BCL2 and acute myeloid leukemia: Venetoclax (ABT-199) is an oral selective B-cell lymphoma 2 (BCL-2) inhibitor FDA-approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myelogenous leukemia (AML)26–28 with biological rationale for evaluation in plasma cell disorders.